FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and a method of reducing cancer induced cachexia in a mammal, comprising administering class 1 and 2b HDAC inhibitor to said mammal in an amount effective to maintain a mammalian body weight, compared to a mammal that does not receive HDAC class 1 and 2b inhibitor. Group of inventions also relates to a method of supporting the skeletal muscle mass in a mammal having cancer, where the skeletal muscle mass is reduced by cancer, involving administering class 1 and 2b HDAC inhibitor to said mammal.
EFFECT: group of inventions provides reduced cancer-induced cachexia.
9 cl, 10 ex, 11 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF MYOSTATIN ANTAGONISTS, COMBINATION CONTAINING THEM AND THEIR USE | 2016 |
|
RU2781401C2 |
| TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| METHODS FOR CANCER TREATMENT USING AUTOPHAGY INHIBITOR BASED ON THIOXANTHONE | 2011 |
|
RU2627588C2 |
| METHOD OF FINAL DIFFERENTIATION INDUCTION | 2010 |
|
RU2530648C2 |
| METHOD OF INDUCING TERMINAL DIFFERENTIATION | 2003 |
|
RU2394022C2 |
| ANTIBODY AGAINST IGF-I RECEPTOR | 2018 |
|
RU2785305C2 |
| APPLICATION OF NUTRIENT COMPOSITION FOR MUSCULAR FUNCTION AND DAILY ACTIVITY IMPROVEMENT | 2009 |
|
RU2636162C2 |
| NUTRITIONAL COMPOSITION FOR IMPROVEMENT OF MUSCLE FUNCTIONS AND DIURNAL ACTIVITY | 2009 |
|
RU2506825C2 |
| HYSTONE DESACETYLASE INHIBITORS FROM NOVEL BENZAMIDE DERIVATIVES WITH STRONG DIFFERENTIAL ANTI-PROLOFERATIVE ACTIVITY | 2004 |
|
RU2364589C2 |
